APRE stock news
This page provides real-time market news, earnings updates, and company announcements related to Aprea Therapeutics, Inc. (APRE).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-04-14 16:44 EST
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Finviz2026-02-17 13:06:08
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
Finviz2026-02-18 13:06:39
Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars
Finviz2026-02-18 19:06:37
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Finviz2026-03-16 12:03:48
APREs profit surpasses expectations, but masks a 98% plunge in sales and an ongoing downward trend
101 finance2026-03-17 03:15:48
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
Finviz2026-03-30 12:03:46
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
Finviz2026-03-30 12:03:44
APRE Surges 9.8% Pre-Market With No Clear Catalyst
101 finance2026-03-30 12:33:49
Aprea’s $30 million funding may lead to significant dilution with the 2028 deadline approaching
101 finance2026-03-31 00:12:46
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
Finviz2026-04-01 12:33:44
APRE Breaks Key Resistance—But Bears Still Lurk Below
101 finance2026-04-10 17:36:54
APREs profit surpasses expectations, but masks a 98% plunge in sales and an ongoing downward trend
101 finance2026-03-17 03:15:48
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
Finviz2026-03-30 12:03:46
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
Finviz2026-03-30 12:03:44
APRE Surges 9.8% Pre-Market With No Clear Catalyst
101 finance2026-03-30 12:33:49
Aprea’s $30 million funding may lead to significant dilution with the 2028 deadline approaching
101 finance2026-03-31 00:12:46
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
Finviz2026-04-01 12:33:44
APRE Breaks Key Resistance—But Bears Still Lurk Below
101 finance2026-04-10 17:36:54
APRE stock chart
APRE stock detailsAPRE stock price change
On the last trading day, APRE stock closed at 0.84 USD, with a price change of -8.25% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more